GlassScriptPhysician profile
Rakesh K Chandra
NPI 1255389623
$380,907.00
in general payments reported to CMS, 2019-2025
26 companies · $119K in 2025
The $119K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $21K · 2021: $60K · 2022: $36K · 2023: $19K · 2024: $105K · 2025: $119K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $205K · Travel and Lodging: $20K · Consulting Fee: $9,215 · Food and Beverage: $8,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $205,262.00 |
| Travel and Lodging | $19,557.31 |
| Consulting Fee | $9,215.00 |
| Food and Beverage | $8,517.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $180,982.53 | 2019-2025 | Dupixent |
| Genzyme Corporation | $140,826.76 | 2019-2025 | |
| Optinose US, INC. | $17,457.38 | 2019-2024 | |
| Gyrus Acmi, INC. | $11,475.00 | 2019-2023 | |
| Glaxosmithkline, LLC. | $6,686.60 | 2021-2025 | Nucala |
| Celgene Corporation | $5,000.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $3,413.44 | 2020-2022 | |
| Acclarent, INC | $2,545.58 | 2019-2023 | Trudi Nav Cable, Acclarent Navwire, Acclarent Aera |
| Integra Lifesciences Corporation | $2,282.02 | 2024-2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Aerin Medical INC. | $1,888.24 | 2020-2025 | |
| Baxter Healthcare | $1,622.47 | 2019 | |
| Alk-Abello, INC | $1,398.21 | 2019 | |
| Medtronic, INC. | $1,304.28 | 2021-2025 | Stealthstation S8 Platform, Propel, Straightshot |
| Medtronic USA, INC. | $950.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $681.32 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $641.00 | 2021-2024 | Core |
| Intersect Ent, INC. | $609.95 | 2019-2021 | |
| Inspire Medical Systems, INC. | $520.08 | 2019-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $271.04 | 2019-2024 | Spravato, Invega Sustenna |
| Smith+Nephew, INC. | $120.15 | 2019 | |
| Abbvie INC. | $115.93 | 2025 | |
| Genentech, INC. | $38.68 | 2021-2022 | |
| Next Science LLC | $36.47 | 2019 | |
| Braeburn INC. | $24.46 | 2025 | Brixadi |
| Xoran Technologies LLC | $15.41 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.